(E,1R,5S)-N-methoxy-6,6-dimethylbicyclo[3.1.1]heptan-2-imine | 1071433-46-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (E,1R,5S)-N-methoxy-6,6-dimethylbicyclo[3.1.1]heptan-2-imine
• CAS: 1071433-46-9
• 化学式: C₁₀H₁₇NO
• 分子量: 167.251
• InChiKey: ZIRVKTQWZHEGDQ-JZGIUJARSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (1R)-(+)-诺蒎酮 、 甲氧基胺盐酸盐 在 吡啶 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 、 (E,1R,5S)-N-methoxy-6,6-dimethylbicyclo[3.1.1]heptan-2-imine
  参考文献：
  名称：

  Stereocontrolled α-Alkylation of Oxime Ether Derived from Terpene: Efficient Synthesis of New Chiral γ- and δ-Amino Alcohols

  摘要：

  (+)-莨菪酮肟醚与各种亲电体发生烷基化反应，可获得相应的加合物，且具有完全的立体选择性。进一步还原肟醚可轻松获得新的手性δ和δ-氨基醇，这对催化和不对称合成具有极大的兴趣。

  DOI：

  10.1055/s-2008-1078492

文献信息

• INHIBITORS OF INFLUENZA VIRUSES REPLICATION
  申请人：Charifson Paul S.

  公开号：US20120171245A1

  公开（公告）日：2012-07-05

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒的复制、减少生物样本或患者中流感病毒量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的由结构公式（I）表示的化合物： 或其药用可接受盐，其中结构公式（IA）的值如本文所述。由结构公式（IA）或其药用可接受盐表示的化合物，其中结构公式（IA）的值如本文所述。药物组合物包括有效量的上述化合物或其药用可接受盐，以及药用可接受载体、佐剂或车辆。
• Process for the diastereoselective alkylation of an ether oxime of the compound nopinone and novel intermediates for the synthesis of diastereospecific 2-amino-nopinone derivatives substituted on carbon 3
  申请人：Caille Jean-Claude

  公开号：US20070225516A1

  公开（公告）日：2007-09-27

  The invention provides the diastereoselective alkylation of optically active nopinone to form the compound of formula (I) according to scheme A below: in which: R is a C 5-15 alkyl group; R1 is especially a C 1-15 alkyl, C 2-15 alkenyl or C 2-15 alkynyl group or a C 5-15 aryl, each group optionally being substituted; and X is a halogen atom; and the configuration of the compound of formula (I) is either (E) or (Z) or a mixture of the two. The compound of formula (I) is a valuable synthetic intermediate.

  该发明提供了对光学活性的诺皮酮进行立体选择性烷基化，形成如下方案A中的化合物的公式(I)：其中：R是C5-15烷基基团；R1特别是C1-15烷基，C2-15烯基或C2-15炔基团或C5-15芳基，每个基团可选择性地被取代；X是卤素原子；化合物的式(I)的构型为(E)或(Z)或两者的混合物。化合物的式(I)是一种有价值的合成中间体。
• Inhibitors of influenza viruses replication
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10039762B2

  公开（公告）日：2018-08-07

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的结构式（I）所代表的化合物： 或其药学上可接受的盐，其中结构式（IA）的值如本文所述。一种化合物由结构式（IA）或其药学上可接受的盐表示，其中结构式（IA）的值如本文所述。药物组合物包含有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• US7390926B2
  申请人：——

  公开号：US7390926B2

  公开（公告）日：2008-06-24
• US8829007B2
  申请人：——

  公开号：US8829007B2

  公开（公告）日：2014-09-09